Answers are grounded in this paper and cite their sources.
Purpose: Rectal spacers, such as stabilized hyaluronic acid (sHA), are used to reduce rectal radiation dose and associated toxicities. Although they have a favorable safety profile, rectal wall infiltration (RWI) can occur. The aim of this study was to evaluate the management and outcomes of patients with RWI after sHA spacer insertion. Materials and Methods: We conducted a retrospective analysis of patients with prostate cancer who developed RWI after spacer insertion between 2021 and 2024 in Australia. Data included patient characteristics, RWI grades and volume, management strategies (reversal or observation), and delays and toxicities related to radiation therapy (RT). Statistical tests were used to assess associations between RWI volume, grade, management decisions, and delays in RT. Results: Among 5788 spacer patients, 16 cases of RWI (0.3%) were identified. Three patients (18.7%) had grade 1, 7 (43.8%) had grade 2, and 6 (37.5%) had grade 3 RWI. The median infiltration volume was 3.0 mL. Higher infiltration volumes were associated with more severity grade (Spearman rho = 0.93, P < .001). Patients with infiltration volumes of 3 mL or greater were more likely to experience delays, with 7 requiring reversal procedures. All successfully resumed RT without major complications. By contrast, 9 patients with infiltration volumes < 3 mL had either no delays or short delays < 2 weeks. Conclusions: sHA spacers are generally safe for prostate cancer treatment. Careful monitoring and individualized management can optimize outcomes in cases of RWI.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: